Minirin - Use | Dosage | Side Effects
Minirin is a medicine that contains desmopressin as an active substance. This drug is a synthetic analogue of antidiuretic hormone (ADH) better known as vasopressin. Vasopressin is a hormone produced by pituitary gland and its main role is to regulate the kidney function by increasing water reabsorption in the kidneys, concentrating the urine and decreasing its volume.
Minirin tablets are used to treat the following diseases:
- Diabetes insipidus - a form of diabetes characterized by a kidney's inability to concentrate urine, resulting in excessive urination (polyuria) that lead to increased thirst (polydipsia).
- Nocturnal enuresis (loss of bladder control at night) in children above the age of 5
- Nocturia in adults. Nocturia is characterized as overproduction of urine during the night.
Contraindications and precautions
Mininin is contraindicated in patients with moderately severe or severe renal impairment (creatinine clearance less than 50 ml / min), as well as in patients who are allergic to the active substance - desmopressin.
This medicine should not be used in patients who are taking diuretics (e.g. furosemide, spironolactone, amiloride, bumetanide, triamterene, and hydrochlorothiazide), as well as in patients with low blood sodium levels (so-called hyponatraemia).
Patients who have syndrome of inappropriate anti-diuretic hormone secretion (SIADH) should not use this medicine.
It is very important to limit fluid intake while using this medication, in order to reduce the risk of water intoxication and hyponatraemia.
Use of this medication in patients with severe cardiovascular disorders is not recommended.
The risk of hyponatraemia is higher if you have any of the following conditions:
- Cystic fibrosis
- Difficult urination
- Any disorder / condition that can cause electrolyte and water imbalance (diarrhea, vomiting, or fever)
Minor, pregnancy and lactation
According to the FDA, this drug belongs to group B because animal studies have not revealed potential harmful effects to the fetus, but for now there are not enough clinical studies in pregnant women. The results of a study conducted in Sweden showed that the incidence of birth defects in newborns whose mothers took this medication did not differ statistically significantly from placebo, but the statistical power of this study is low, so the results must be taken with caution.
This medicine should be used during pregnancy only if clearly needed.
There is no information on whether this drug is excreted in breast milk or not, and therefore caution should be exercised if this medicine is administered during breastfeeding. Avoid breastfeeding while using this drug.
Dosage is individual for every patient, and the doctor will determine which dose is best for you based on the severity of your condition.
The usual initial dose for the treatment of diabetes insipidus is 50 micrograms (0.05 mg) twice a day. The dose should be gradually increased until the appropriate effects are achieved.
The usual maintenance dose for the treatment of diabetes insipidus is 100-200 micrograms (0.1-0.2 mg) three times a day.
The usual initial dose for the treatment of primary night enuresis in children older than 5 years is 200 micrograms half an hour before bedtime. If no appropriate effect is achieved, the dose may be increased to 400 mg half an hour before bedtime. The maximum daily dose for the treatment of primary night enuresis is 600 micrograms.
The usual initial dose for the treatment of nocturia is 100 micrograms half an hour before bedtime. If no adequate effects are achieved, the dose may be increased up to 400 mg.
Take the tablet two hours before or two hours after a meal, because the food can reduce the effect of this medicine.
Minirin tablets should not be administered concurrently with the following medicines:
- Antidepressants, such as:
Antihistamines, such as:
Fibrates, such as:
- Non-steroidal anti-inflammatory drugs, such as:
- Narcotic analgesics, such as:
- Medicines used to treat diarrhea (e.g. loperamide).
- Drugs used to treat type 2 diabetes mellitus (e.g. glimepiride, metformin, gliclazide, glyburide, and others).
The most common adverse effect associated with Minirin tablets is headache.
In addition, commonly reported adverse effects of Minirin tablets include:
- Nausea and vomiting
- Pain in the abdomen
The following adverse reactions may occur occasionally:
- Visual disturbances
- Difficulty breathing
- Postural hypotension
- Flu-like symptoms (cough, sore throat and fever)
The following adverse reactions have been rarely reported:
- Mood swings
- Allergic reactions
Frequency of following adverse reactions is not known:
- Emotional disorders
- accessdata link
Information on this website are provided for educational purposes only and are not intended for medical advice, diagnosis or treatment.
If you have any concerns or questions about your health, you should always consult with a physician or other health-care professional.